- Home
- IRWD
as of 01-22-2026 3:46pm EST
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 520.6M | IPO Year: | 2010 |
| Target Price: | $5.74 | AVG Volume (30 days): | 7.4M |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.53 - $5.78 | Next Earning Date: | 02-26-2026 |
| Revenue: | $338,987,000 | Revenue Growth: | -10.42% |
| Revenue Growth (this year): | -13.14% | Revenue Growth (next year): | 37.22% |
AI-Powered IRWD Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Ironwood Pharmaceuticals Inc. (IRWD)
Principal Accounting Officer
Avg Cost/Share
$4.60
Shares
35,416
Total Value
$162,913.60
Owned After
276,809
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$3.32
Shares
6,016
Total Value
$19,973.12
Owned After
235,264
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Silver Ronald | IRWD | Principal Accounting Officer | Jan 5, 2026 | Sell | $4.60 | 35,416 | $162,913.60 | 276,809 | |
| Gaskins Tammi L | IRWD | Chief Commercial Officer | Nov 17, 2025 | Sell | $3.32 | 6,016 | $19,973.12 | 235,264 |
Compare IRWD vs Leading Stocks
See how IRWD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IRWD Ironwood Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.